Has Kimberly Cockerham, MD received payments from drug or device companies?

Yes. Drug and device makers reported $183,450 in general payments to Kimberly Cockerham, MD across 221 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kimberly Cockerham, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kimberly Cockerham, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kimberly Cockerham, MD

Neuro-ophthalmology · San Diego, CANPI 1366493629

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $123,493 of the $183,450 with a category attached, or 67.3%. Amgen accounts for 92.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $56,908 and has fallen 80.3% since, to $11,233 in 2025. Among neuro-ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$183,450in general payments, 2019–2025

Across 221 payments — averaging $830.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$169K
Genentech USA, Inc.$8K
Argenx US, Inc.$5K
Janssen Global Services, LLC$605
AstraZeneca$389
Merz North America, Inc.$162
plus $755 from 13 others

$260,405in research payments, 2019–2025

Across 84 payments — averaging $3100.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$175K
Genentech, Inc.$56K
Argenx US, Inc.$28K

What the payments were for

Consulting fees$44,70624%
Speaking & faculty fees$123,49367%
Travel & lodging$9,7705%
Food & beverage$5,4403%
Education$410%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	172	$168,687
Genentech USA, Inc.	5	$7,977
Argenx US, Inc.	2	$4,875
Janssen Global Services, LLC	1	$605
AstraZeneca	14	$389
Merz North America, Inc.	3	$162
Mallinckrodt Hospital Products Inc.	4	$134
Mallinckrodt Enterprises LLC	1	$120
Oyster Point Pharma, Inc.	4	$83
Topcon Healthcare, Inc.	1	$75
Dompe US, Inc.	2	$54
Alcon	1	$52
ANI Pharmaceuticals, Inc.	2	$50
Tarsus Pharmaceuticals, Inc.	1	$40
Bausch & Lomb Americas Inc.	2	$37
Galderma Laboratories, L.p.	2	$31
AbbVie	2	$31
UCB, Inc.	1	$30
Aerie Pharmaceuticals, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEPEZZA$163,428
VYVGART HYTRULO$4,800
Enspryng$4,659
UPLIZNA$2,045
ACTHAR$120

How this compares

$183,450 in reported general payments places this provider in the 95th percentile of 25 neuro-ophthalmology providers in California.

See all neuro-ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$178,759

Medicare patients

333

Services billed

1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TobradexTobramycin/Dexamethasone	81	$21,255
Pyridostigmine Bromide	42	$1,747
ErythromycinErythromycin Base	61	$667
MoxifloxacinMoxifloxacin Hcl	16	$638
Tobramycin-DexamethasoneTobramycin/Dexamethasone	13	$583
Doxycycline Monohydrate	18	$351
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	31	$315
Prednisone	14	$32

Paid to pharmacies, not to this prescriber.

Other neuro-ophthalmology in San Diego

Tim KimSan Diego$179
Vivek PatelIrvine$81K
Kimberly GokoffskiOrange$36K
Syed Khizer KhaderiStanford$35K
Nafiseh HashemiEncino$12K
Yin LiuSacramento$11K
Samuel SpiegelPasadena$8K
Howard KraussLos Angeles$7K
Heather MossStanford$4K
Benjamin GhiamEncino$3K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →